186 filings
Page 5 of 10
CORRESP
rvkrun9obd7ess
20 Dec 19
Correspondence with SEC
12:00am
UPLOAD
v9s 6y7kru
4 Dec 19
Letter from SEC
12:00am
6-K
5rhrmn2i c8cjzcep5b
13 Nov 19
Current report (foreign)
6:34am
6-K
mthlfvz 7fsz
6 Nov 19
Current report (foreign)
6:48am
6-K
b7bc vo7gp64nce
20 Sep 19
AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program
7:53am
6-K
gv7uha y2clvwv
14 Aug 19
Current report (foreign)
12:00am
S-8
gi2gvaea1
5 Aug 19
Registration of securities for employees
4:18pm
6-K
steo33
1 Aug 19
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
7:55am
6-K
7phv jg0sa
17 Jul 19
Current report (foreign)
8:08am
6-K
wdv6u3hrb9u
11 Jul 19
Current report (foreign)
8:20am
6-K
j7snpo
28 Jun 19
Current report (foreign)
4:45pm
6-K
okbnf2rli sk
4 Jun 19
Invitation to the Ordinary Shareholders' Meeting
7:22am
6-K
6zxgz5neto6yk
15 May 19
Current report (foreign)
7:43am
20-F/A
rtrp6ljefw6m0 p5ob8f
19 Apr 19
Annual report (foreign) (amended)
5:07pm
6-K
bluoyjq su4bw
21 Mar 19
Current report (foreign)
7:44am
6-K
g20r4 6vw9z0
20 Feb 19
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
9:00am
6-K
bv19 vszt68ev0gdioq
8 Feb 19
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
6:02am
6-K
1co7zz
30 Jan 19
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
6:00am
6-K
mi137a o2
23 Jan 19
Current report (foreign)
6:36am